GlaxoSmithKline Pharmaceuticals Limited has submitted a regulatory disclosure to BSE Limited and The National Stock Exchange of India Limited regarding the outcome of analyst and institutional investor meetings.
The disclosure was made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company has uploaded the audio recording of these meetings to its official investor relations website at: https://india-pharma.gsk.com/en-in/investors/analyst-meets/
The letter was signed by Ajay Avinash Nadkarni, who holds the positions of Vice President – Administration, Real Estate & Company Secretary at GlaxoSmithKline Pharmaceuticals Limited.
The company's Corporate Identification Number (CIN) is L24239MH1924PLC001151.